RS54074B1 - Methods and compositions comprising supramolecular constructs - Google Patents

Methods and compositions comprising supramolecular constructs

Info

Publication number
RS54074B1
RS54074B1 RS20150393A RSP20150393A RS54074B1 RS 54074 B1 RS54074 B1 RS 54074B1 RS 20150393 A RS20150393 A RS 20150393A RS P20150393 A RSP20150393 A RS P20150393A RS 54074 B1 RS54074 B1 RS 54074B1
Authority
RS
Serbia
Prior art keywords
seq
antigenic peptide
antibody
peptide
antigenic
Prior art date
Application number
RS20150393A
Other languages
Serbian (sr)
Inventor
Yves NICOLAU CLAUDE
Ruth Greferath
David Hickman
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/783,975 external-priority patent/US20040242845A1/en
Priority claimed from US10/958,211 external-priority patent/US8663650B2/en
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of RS54074B1 publication Critical patent/RS54074B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Konformaciono senzibilno antitelo koje se može dobiti antigenim konstruktom koji sadrži antigeni peptid koji ima aminokiselinsku sekvencu p amiloida izabranu iz grupe koja se sastoji od SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 i SEQ ID NO: 5, ili njegov fragment, pri čemu je antigeni peptid ili njegov aktivni fragment modifikovan tako da ima kovalentno vezani polietilen glikol, po jedan na svakom kraju, i rekonstituisan je u lipozomu, koje antitelo ima specifičnost vezivanja za antigeni peptid i(a) ispoljava konformacionu senzibilnost i afinitet za antigen, koji je povećan u poređenju sa antitelom pobuđenim sa palmitoilovanim antigenim peptidom; i(b) indukuje tranziciju amiloidnog peptida iz β-ploče u α-zavojnicu.Prijava sadrži još 11 patentnih zahteva.A conformational sensitive antibody obtainable from an antigenic construct comprising an antigenic peptide having the amino acid sequence of p amyloid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, or a fragment thereof, wherein the antigenic peptide or active fragment thereof is modified to have covalently bound polyethylene glycol, one at each end, and is reconstituted in a liposome, which antibody has specificity for binding to the antigenic peptide and ( a) exhibits conformational sensitivity and affinity for the antigen, which is increased compared to the antibody excited by the palmitoylated antigenic peptide; and (b) induces the transition of the amyloid peptide from the β-plate to the α-coil. The application contains 11 more claims.

RS20150393A 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs RS54074B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/783,975 US20040242845A1 (en) 2003-02-21 2004-02-20 Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US10/958,211 US8663650B2 (en) 2003-02-21 2004-10-04 Methods and compositions comprising supramolecular constructs

Publications (1)

Publication Number Publication Date
RS54074B1 true RS54074B1 (en) 2015-10-30

Family

ID=46395388

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20150393A RS54074B1 (en) 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs

Country Status (11)

Country Link
JP (1) JP4934433B2 (en)
KR (1) KR101277004B1 (en)
CY (1) CY1116316T1 (en)
DK (1) DK2465533T3 (en)
ES (2) ES2385226T3 (en)
HK (2) HK1130698A1 (en)
HR (1) HRP20150612T1 (en)
HU (1) HUE025186T2 (en)
PT (1) PT2465533E (en)
RS (1) RS54074B1 (en)
SI (1) SI2465533T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010224824B2 (en) * 2009-03-18 2014-02-20 Ac Immune S.A. Method for therapeutic use
CN103189050B (en) * 2010-10-26 2017-09-29 Ac免疫有限公司 The construct based on liposome comprising the peptide modified by hydrophobic part

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
WO1999041279A2 (en) * 1998-02-13 1999-08-19 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
EP1259563B2 (en) * 1999-12-22 2016-08-10 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.

Also Published As

Publication number Publication date
PT2465533E (en) 2015-06-24
HUE025186T2 (en) 2016-02-29
ES2385226T3 (en) 2012-07-19
DK2465533T3 (en) 2015-04-20
KR101277004B1 (en) 2013-06-24
ES2385226T9 (en) 2013-10-10
CY1116316T1 (en) 2017-02-08
HK1172260A1 (en) 2013-04-19
SI2465533T1 (en) 2015-07-31
HRP20150612T1 (en) 2015-07-03
JP4934433B2 (en) 2012-05-16
JP2007527870A (en) 2007-10-04
HK1130698A1 (en) 2010-01-08
KR20120097546A (en) 2012-09-04
ES2539262T3 (en) 2015-06-29

Similar Documents

Publication Publication Date Title
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
RS51635B (en) Cripto blocking antibodies and uses thereof
CY1118037T1 (en) ANTIBODIES AGAINST AVETA AND THEIR USE
CY1106876T1 (en) PACKAGING AND METHOD OF PROTECTION OF ESM-1
RS52769B (en) Compositions and methods for increasing bone mineralization
RS54133B1 (en) Anti-il-6 antibodies, compositions, methods and uses
US7485321B2 (en) Peyer's patch and/or M-cell targeting ligands
NO20063026L (en) antibodies
CY1114851T1 (en) IL-1BIT BINDING antibodies and their fragments
FR2889416B1 (en) COMPOSITION OF PEAS PROTEINS
HUP0004639A2 (en) Chlamydia protein, gene sequence and uses thereof
RS54056B1 (en) Anti-cd38 human antibodies and uses therefor
DE60233532D1 (en) SYNTHETIC ODE APPLICATIONS BINDING TO PROTEIN PHOSPHATASE 2A
BR0012919A (en) Vaccine for use in the prophylaxis and / or treatment of white spot syndrome in crustaceans, structural protein derived from white point syndrome virus, nucleic acid sequence, use of a structural protein, pharmaceutical composition, antibodies, vaccine or pharmaceutical formulation, and, diagnostic kit for wssv detection
BR0211296A (en) Immunogenic peptide derived from subgroup a or b vrs protein g, nucleic acid sequence, pharmaceutical composition, polyclonal or monoclonal antibodies, diagnostic kit, use of an immunogenic peptide, and, conjugate
DE60043620D1 (en) MAGE-A1 PEPTIDES PRESENTED BY CLASS II HLA MOLECULE
DE60331677D1 (en) KIT FOR THE STUDY OF HUMAN LOW MOLECULAR WEIGHT CD14 AND ANTIBODIES
JP2002505841A5 (en)
ATE438409T1 (en) PROTEIN CONTAINING VECTORS FOR INTRODUCING MOLECULES INTO CD11B EXPRESSING CELLS
RS54074B1 (en) Methods and compositions comprising supramolecular constructs
RS50831B (en) An isolated antibody or antibody fragment which specifically binds to the rg1 polypeptide
DE60127113D1 (en) GD3 MIMETIC PEPTIDES
FR2815634B1 (en) MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUSES
WO2006038101A3 (en) Novel cancer associated antibodies and antigens and their use in cancer diagnosis
WO2003089472A3 (en) Anti-nls scfv and peptides and uses thereof in nuclear import inhibition